B-type natriuretic peptide blood levels identify patients with non-ST elevation acute coronary syndromes at high risk for complications during intravenous beta-blocker infusion

References

• Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, . ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction): Developed in collaboration with the American College of Emergency Physicians, American College of Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2007;50:e1–157.
   PubMed Web of Science ®Google Scholar
• Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2:57–66.
   PubMedGoogle Scholar
• Acute myocardial infarct size reduction by timolol administration. The International Collaborative Study Group. Am J Cardiol. 1986;57:28F–33F.
   Google Scholar
• Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96:183–91.
   PubMed Web of Science ®Google Scholar
• AAl-Reesi A, Al-Zadjali N, Perry J, Fergusson D, Al-Shamsi M, Al-Thagafi M, . Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. CJEM 2008;10:215–23.
   Google Scholar
• Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, . COMMIT (clopidogrel and metoprolol in myocardial infarction trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1622–32.
   PubMed Web of Science ®Google Scholar
• Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, . 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction). Circulation 2008;117: 296–329.
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, . ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–45.
   PubMedGoogle Scholar
• Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F . Task force for diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598–660.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:263.
   Google Scholar
• The MIAMI trial research group. Metoprolol in acute myocardial infarction. A randomized placebo controlled international trial. Eur Heart J. 1985;6:199–226
   PubMed Web of Science ®Google Scholar
• Loopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, ; Task force on beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25: 1341–62.
   Google Scholar
• Arntz HR, Bossaert LL, Danchin N, Nikolaou NI. European Resuscitation Council guidelines for resuscitation 2010 section 5. Initial management of acute coronary syndromes. Resuscitation 2010;81:1353–63.
   Google Scholar
• Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra short acting b-blocker: esmolol. Int J of Clin Pharmacol Ther. 1995;33:212–8.
   PubMed Web of Science ®Google Scholar
• Sung RJ, Lori Blanski RN, Kirshenbaum J, MacCosbe P, Pharm D, Turlapaty P and the esmolol research group. Clinical experience with esmolol, a short acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J Clin Pharmacol. 1986; 26:A15–A26.
   Google Scholar
• Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, . Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:89–91.
   Google Scholar
• Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DTh. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol. 2000;23:285–8.
   PubMedGoogle Scholar
• Farmakis D, Filippatos G, Tubaro M, Peacock WF, DiSomma S, Mueller C, . Natriuretic peptides in acute coronary syndromes: Prognostic value and clinical implications. Congest Heart Fail. 2008;14(Suppl 1):25–9.
   Google Scholar
• Hammerer-Lercher A, Puschendorf B, Mair J. Cardiac natriuretic peptides: new laboratory parameters in heart failure patients. Clin Lab. 2001;47:265–77.
   Google Scholar
• Hery E, Jourdain P, Funck F, Bellorini M, Loiret J, Thebault B, . Prediction of intolerance to beta blocker therapy in chronic heart failure patients using BNP. Ann Cardiol Angeiol. 2004; 53:298–304.
   Google Scholar
• Nikolaou NI, Kyriakides ZS, Tsaglis EP, Antonatos DG, Kartsagoulis EC, Tsigas DL. The measurement of brain natriuretic peptide may detect acute myocardial ischemia in patients with ongoing chest pain. Int J Cardiol. 2005;101:223–9.
   Google Scholar
• Kirshenbaum JM, Kloner RA, Antmann EM, Braunwald E. Use of an ultra-short acting β-blocker in patients with acute myocardial ischemia. Circulation 1985;72:873–80.
   Google Scholar
• Wallis DE, Pope C, Littman W, Scanlon P. Safety and efficacy of esmolol in unstable angina pectoris. Am J Cardiol. 1988;62: 1033–7.
   Web of Science ®Google Scholar
• Hohnloser SH, Meinertz T, Klingenheben T, Syndow B, Just H. Usefulness of esmolol in unstable angina pectoris. Am J Cardiol. 1991;67:1319–23.
   Google Scholar
• Barth C, Ojile M, Pearson A, Labovitz A. Ultra short-acting intravenous b-adrenergic blockade as add-on therapy in acute unstable angina. Am Heart J. 1991;121:782–8.
   Web of Science ®Google Scholar
• Pfisterer M, Cox JL, Granger CB, Brener SJ, Naylor CD, Califf RM, . Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global utilization of streptokinase and TPA (alteplase) for occluded coronary arteries. J Am Coll Cardiol. 1998;32: 634–40.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis.1985;27:335–71.
   PubMed Web of Science ®Google Scholar
• Herlitz J, Waagstein F, Lindqvist J, Swedberg K, Hjalmarson A. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg metoprolol trial). Am J Cardiol. 1997;80:40J–4J.
   PubMed Web of Science ®Google Scholar
• Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, . Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43:1773–9.
   PubMed Web of Science ®Google Scholar
• Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000;84:421–4.
   PubMed Web of Science ®Google Scholar
• Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, . Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558–64.
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, . N-terminal pro-B-type natriuretic peptide and long term mortality in acute coronary syndromes. Circulation 2002;2913–8.
   Google Scholar
• McCollough PA, Omland T, Maisel A. B-type natriuretic peptides: A diagnostic breakthrough to clinicians, Rev Cardiovasc Med. 2003;4:72–80.
   Google Scholar
• Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, . Plasma brain natriuretic peptide as an indicator of LV systolic function and long term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963–9.
   PubMed Web of Science ®Google Scholar
• Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28: 190–202.
   PubMed Web of Science ®Google Scholar
• Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol. 1985;56:3F–13F.
   PubMed Web of Science ®Google Scholar
• Iskandrian AS, Bemis CE, Hakki AH, Panidis I, Heo J, Toole JG, . Effects of esmolol in patients with left ventricular dysfunction. J Am Coll Cardiol. 1986;8:225–3.
   Google Scholar